Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of BEBT-908 for relapsed or refractory peripheral T-cell lymphoma
CTR20210170Phase 2Completed
- Sponsor
- BeBetter Med
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifupinostat in peripheral T-cell lymphoma (PTCL), Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), subcutaneous panniculitis-like T-cell lymphoma (SPTCL), sponsored by BeBetter Med. Started Sep 2021; status: completed.
02
Drugs
ifupinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)angioimmunoblastic T-cell lymphoma (AITL)anaplastic large cell lymphoma (ALCL)subcutaneous panniculitis-like T-cell lymphoma (SPTCL)
Beyond the preview
Go deeper on CTR20210170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210170.